[1] WHO Bacterial Priority Pathogens List. Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. Geneva: World Health Organization; 2024. Licence: CC BY-NC-SA 3.0 IGO. https://iris.who.int/server/api/core/bitstreams/1a41ef7e-dd24-4ce6-a9a6-1573562e7f37/content.
[2] Di Pilato V, De Angelis LH, Aiezza N, Baccani I, Niccolai C, Parisio EM, et al. Resistome and virulome accretion in an NDM-1-producing ST147 sublineage of Klebsiella pneumoniae associated with an outbreak in Tuscany, Italy: a genotypic and phenotypic characterisation. Lancet Microbe 2022;3(3):e224 − 34.
[3] Martin MJ, Corey BW, Sannio F, Hall LR, MacDonald U, Jones BT, et al. Anatomy of an extensively drug-resistant Klebsiella pneumoniae outbreak in Tuscany, Italy. Proc Natl Acad Sci USA 2021;118(48):e2110227118.
[4] Zhou HJ, Guo CY, Cui ZG, Hu JR, Du XL, Sun Y, et al. The epidemiology and hypervirulence of Klebsiella pneumoniae ST23 unveil epidemic risks in China and worldwide. Lancet Reg Health West Pac 2025;62:101661.
[5] Lytras S, Lamb KD, Ito J, Grove J, Yuan K, Sato K, et al. Pathogen genomic surveillance and the AI revolution. J Virol 2025;99(2):e01601 − 24.
[6] David S, Reuter S, Harris SR, Glasner C, Feltwell T, Argimon S, et al. Epidemic of carbapenem-resistant Klebsiella pneumoniae in Europe is driven by nosocomial spread. Nat Microbiol 2019;4(11):1919 − 29.
[7] Loconsole D, Sallustio A, Sacco D, Santantonio M, Casulli D, Gatti D, et al. Genomic surveillance of carbapenem-resistant Klebsiella pneumoniae reveals a prolonged outbreak of extensively drug-resistant ST147 NDM-1 during the COVID-19 pandemic in the Apulia region (Southern Italy). J Glob Antimicrob Resist 2024;36:260 − 6.
[8] Kitts PA, Church DM, Thibaud-Nissen F, Choi J, Hem V, Sapojnikov V, et al. Assembly: a resource for assembled genomes at NCBI. Nucl Acids Res 2016;44(D1):D73 − 80.
[9] Parks DH, Imelfort M, Skennerton CT, Hugenholtz P, Tyson GW. CheckM: assessing the quality of microbial genomes recovered from isolates, single cells, and metagenomes. Genome Res 2015;25(7):1043 − 55.
[10] Guo CY, Chen Q, Fan GM, Sun Y, Nie JY, Shen ZH, et al. gcPathogen: a comprehensive genomic resource of human pathogens for public health. Nucl Acids Res 2024;52(D1):D714 − 23.
[11] Fan GM, Guo CY, Zhang Q, Liu DM, Sun QL, Cui ZG, et al. A secure visualization platform for pathogenic genome analysis with an accurate reference database. Biosafety Health 2024;6(4):235 − 43.
[12] Sharland M, Zanichelli V, Ombajo LA, Bazira J, Cappello B, Chitatanga R, et al. The WHO essential medicines list AWaRe book: from a list to a quality improvement system. Clin Microbiol Infect 2022;28(12):1533 − 5.
[13] Wang LG, Chen H, Zhang YY, Tian Y, Hu XY, Wu J, et al. Global antibiotic consumption and regional antimicrobial resistance, 2010-21: an analysis of pharmaceutical sales and antimicrobial resistance surveillance data. Lancet Glob Health 2025;13(11):e1880 − 91.
[14] Carvalho AG, Belém MGL, Rodrigues RS, Da Silva MEP, dos Santos Dorneles NW, Da Silva Lima NC, et al. Serotype distribution, virulence factors, and antimicrobial resistance profiles of Streptococcus agalactiae (Group B Streptococcus) isolated from pregnant women in the Brazilian Amazon. BMC Microbiol 2025;25(1):361. http://10.1186/s12866-025-04077-2.